SR One
Overview
The venture arm of GlaxoSmithKline and invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
Investment Focus
- Innovative science with potential to impact medical care
- Strong underlying fundamentals
- Clearly defined development pathway
- Novel approaches to addressing diseases
Portfolio Companies
Reach SR One directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about SR One
What sectors does SR One invest in?
SR One invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Redwood City, United States. SR One is listed as a vc in the ConnectSafely investor database.
What stage does SR One invest at?
SR One backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 5M - 50M.
Which regions does SR One invest in?
SR One invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
Who are the partners at SR One?
Team members listed for SR One include Simeon George (Chief Executive Officer and Co-Founder) and Marie Benson (Chief of Staff & Manager, US Operations).
What companies has SR One invested in?
SR One's portfolio includes Turning Point Therapeutics, Zenas BioPharma, Avenzo Therapeutics, Alumis, Avalyn Pharma, Nkarta Therapeutics, Windward Bio and CRISPR Therapeutics.
How do I contact SR One?
SR One's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database